Video

EAU 2018 GU Oncology VL

Development of Urology and Medical Oncology in an Academic Center Level - Interview with Badrinath Konety Details (Length of Discussion: 16 min) Charles Ryan and Badrinath Konety discuss the challenges and promises you see as a chair of a department of urology at a major academic medical center in the US. Topics discussed are avoiding burnout and the quality of life in academia. Specific programs and strategies incorporated at the University of Minnesota including fostering the growth of young science focused...
Exercise in Men with Metastatic Castrate-Resistant Prostate Cancer, the INTERVAL Study - Interview with Fred Saad Details Fred Saad and Charles Ryan discuss the Movember Foundation sponsored, INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer Study (INTERVAL). This is a randomized phase 3 study of exercise in men with metastatic castrate-resistant prostate cancer (mCRPC). The objective of the study is to determine if high intensity aerobic and resistance training plus psychosoc...
Active Surveillance: Who is the Right Patient? - Matt Cooperberg Details Matthew Cooperberg and Charles Ryan discuss active surveillance in the low risk and low volume disease setting. The topics they highlight include defining the appropriate patient for active surveillance in 2018 and reaching a global consensus, how much age factors into active surveillance, how biomarkers and imaging are driving research and decision making in the active surveillance setting and wh...
Quality of Life During Treatment with Chemohormonal Therapy - Alicia Morgans Details Alicia Morgans, MD and Charles Ryan, MD discuss the quality of life between patients with metastatic hormone-sensitive prostate cancer who were treated with ADT+docetaxel and those who were treated with ADT alone. The importance of the study was to understand how different treatments actually affected the individuals receiving them. Biographies: Alicia Morgans, MD, MPH Charles J. Ryan, MD Read Mor...
Minimizing Treatment Burden and Biomarkers in Bladder Cancer - Badrinath Konety Details Badrinath Konety and Alicia Morgans discuss biomarkers in bladder cancer. Concepts highlighted include incorporating clinical and other disease characteristics into biomarkers, so outcomes can be more accurately predicted. Biographies: Badrinath Konety, MD, MBA , is professor and chair at the University of Minnesota, where he holds the Dougherty Family Chair in Uro-Oncology and is Director of the...
Joining Forces to Address Unanswered Questions - The European PEACE Consortium - Interview with Karim Fizazi Details Karim Fizazi and Alicia Morgans discuss various treatment data in the metastatic hormone-sensitive space, including the LATITUDE, CHAARTED and STAMPEDE trials. The European Consortium Prostate Cancer Consortium in Europe (PEACE) trials were designed for the current generation of prostate and advanced prostate cancer patients and was established in 2013 to facilitate large academic clinical trials...
The Utility of PSMA PET In Prostate Cancer Management- Stefano Fanti Details (Length of Discussion: 12 min) Stefano Fanti shares his views of the use of imaging in prostate cancer and where it most useful. This conversations includes discussion on the rapidly developing area of PSMA PET and the clinical implications including in biochemical reoccurrence, targeted radiation and identifying high risk diseases for patients with potential oligometastatic disease. Other key poi...
Discussion on PROSPER: Safety and Efficacy Study of Enzalutamide in Patients with nmCRPC - Thomas Keane Details (Length of Discussion: 7 min) Dr. Thomas Keane reviews the first presentation on the PROSPER study which was a much awaited presentation presented by Dr. Maha Hussain at the recent 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium . Dr. Hussain started her presentation on PROSPER, a phase III randomized double-blind controlled trial, Safety and Efficacy Study of...

EAU 2018 GU Oncology VL

Login